Everest Biolabs, Inc. — Form D
Everest Biolabs, Inc. of WALTHAM, MA, a company, filed a Form D exempt-offering notice with the SEC on 2026-03-11. The offering totals $5.7M, of which $4.3M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2026-03-11
- Form: D
- Accession: 0002116676-26-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $5.7M
- Amount sold: $4.3M
- Remaining: $1.3M
- Investors: 7
- Date of first sale: 2026-02-25
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-576080
Issuer
- Name: Everest Biolabs, Inc.
- CIK: 0002116676
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2024
- Address: 204 SECOND AVE, WALTHAM, MA, 02451
- Phone: 6172140840
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| GEORGE DAABOUL | Director | Waltham, MA |
| DAVID FREEDMAN | Director | Waltham, MA |
| Paul Meister | Director | Waltham, MA |
| Vinit Nijhawan | Director | Waltham, MA |
| David Walt | Director | Cambridge, MA |
| GEORGE DAABOUL | Executive Officer | Waltham, MA |
| DAVID FREEDMAN | Executive Officer | Waltham, MA |
More